Medium term results of HEMA intraocular lenses (Hydroview).
A group of 232 eyes that received a HEMA IOL (Hydroview, Storz Inc.) was followed over a period of six months. Mean visual acuity increased from 0.41 preoperatively to 0.79 post-operatively. During the follow-up period, the visual acuity remained stable in 175 eyes and decreased in 57 eyes, mainly due to progression of ARMD and posterior capsule opacification (PCO). Nine eyes required YAG-laser capsulotomy. Cell migration on the anterior surface of the Hydroview IOL was observed in 100% of the cases after a period of 3 months.